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Paf-acether (pal) and lyso phospholipids induced an oxydative burst on EBV-transformed B lymphocyte cell line. Superoxide anion formation 
measured by lucigenin-dependent chemiluminescence was dependent on both paf concentration and time-course of challenge. Paf Cl80 at 10 PM 
was more potent than its C16:O analogue at the same concentration. Choline-containing phospholipids with 2-acyl (long chain) were inactive. The 
paf antagonists BN 52021 and WEB 2086 structurally unrelated to paf were inactive whereas paf structural analogue CV 3988 inhibited superoxide 
formation induced by paf and lysophospholipids. Such a phospholipid-induced oxydative burst in B cells might exert an effect in the numerous 
pathophysiological situations where large amounts of paf are produced by phagocytic ells. 
B cell line (human); Paf-a&her; Superoxide anion 
1. INTRODUCTION 
In a variety of cells including human lymphoblastoid 
B cells [l] paf-acether (paf, 1-0-hexa/octadecyl-2-- 
acetyl-sn-glycero-3-phosphocholine; for references see 
review in [2]) acts via specific binding sites functionally 
coupled to phospholipase C-initiated 
phosphatidylinositol hydrolysis [3]. The specificity of 
paf binding is evidenced by displacement of radiolabel- 
ed paf with unlabelled paf or with specific paf an- 
tagonists [4]. Paf antagonists such as gingkolides [5] 
triazolobenzodiazepines [6] or structural analogues of 
paf [5,7] are equally very potent inhibitors of cellular 
paf effects [4] suggesting that the biochemical events in- 
itiated by paf are related to occupancy of the specific 
paf binding sites. 
The expression of NADPH-oxidase and the potential 
for stimulus-triggered superoxide anions (02 produc- 
tion) is one of the main features of phagocytes. Recent- 
ly, several reports showed that human B lymphocytes 
were able to form superoxide anions and derived reac- 
tive oxygen radicals when stimulated with PMA or by 
cross-linking of surface immunoglobulins [8]. 
Paf, an extra- and intercellular mediator [2] that 
generates one of the earliest signals in the transmem- 
brane transducing system [3] is also implicated in the 
superoxide formation in phagocytes and polymor- 
phonuclear neutrophils [9, lo]. Paf was also recognized 
to possess immunoregulatory functions in human cells 
[ 111, some of which might be mediated by superoxide 
ions generation in situ by either phagocytes and 
polymorphonuclear neutrophils or other undetermined 
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cell types. We thus tested the hypothesis of paf involve- 
ment in the oxidative burst of EBV-transformed B lym- 
phocyte cell line (EBV-BLCL). 
2. MATERIALS AND METHODS 
Synthetic Cl6:O and C18:O paf, I-0-hexa/octadecyl-2-acetyl-sn- 
glycero-3-phosphocholine (I-0-hexa/octadecyl-2-acetyl-GPC), 
C16:O and C18:O lyso paf, l-0-hexa/octadecyl-GPC, l-O- 
hexadecyl-2-N-methylcarbamyl-GPC and l-O- 
hexadecyl-2-palmitoyl-GPC were obtained from Novabiochem 
(Laufenfingen, Switzerland). Radiolabelled paf (1-0-[‘Hloctadecyl, 
80-120 mCi/mmol or N-methyl-[%], 58 &i/mmol) and OCS scin- 
tillation liquid were from Amersham Int. (UK). Paf antagonists were 
gifts as noted: BN 52021 (Institut Henri Beaufour, Plessis Robinson, 
France), WEB 2086 (Boehringer Ingelheim, Ingelheim, FRG), CV 
3988 (Takeda Chemical Ind., Osaka, Japan). 
2.1. B lymphocyte ceil line establishment 
GLl cell line was obtained after infection of normal B cells using 
B 95.8 supernatant (EBV-producing Marmoset lymphoblastoid cell 
line) as described in [ 121. Cell surface marker analysis was performed 
using an Orthocytofluorograph (model 50 H) by using FITC-labelled 
F(ab’)z fragments of rabbit anti-human IgG and IgM (Jackson Im- 
munoresearch Lab., West Grove, PA, USA) and following FITC 
mouse monoclonal antibodies (Becton Dickinson, Mountain View, 
CA, USA): anti-Leu 12 (B cells), anti-Leu M3 (monocytes), anti-Leu 
4 (T cells). 
2.2. Lucigenin-chemiluminescence measurements 
Chemiluminescence (CL) was measured using the luminometer 
(PICO-Lite, Packard 6100, Downers Grove, IL, USA) as follows: 
200 ~1 of cell suspension (5 x ld cells/ml of MEM medium) was 
transferred into a borosilicated tube and 25 ~1 of the agent to be 
tested was added. The lucigenin solution (25 pl, bis-N- 
methylacridinium nitrate; Sigma, St. Louis, MO, USA) was then 
added to a final concentration of 100 FM. The tubes were transferred 
into the counting chamber of the luminometer with the thermostat set 
at 37°C. Results are expressed in cpm after substraction of the 
background mean value. 
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2.3. fH]paf metabolism by EBV-BLCL 
Cells (5 x 106/ml of MEM Dulbecco medium) were incubated up 
to 20 min at 37°C with 10 ,xM [3H]paf and then extracted with 4 vols 
of absolute ethanol. After centrifugation (1500 x g for 15 min, 20°C) 
supernatants were dried (40°C) under an air stream and the residues 
were further analysed by liquid chromatography [13] using [‘%Z]paf 
as an internal standard. 
3. RESULTS AND DISCUSSION 
Two molecular species of paf were used in this study: 
C18:O and C16:O paf. Both elicited superoxide forma- 
tion in EBV-BLCL. The lucigenin-dependent 
chemiluminescence signal (reflecting O*- formation) 
was dependent on both paf concentration and time- 
course of challenge. Paf C18:O was more potent than its 
C16:O analogue (Fig. 1). [3H]paf (10 PM) added to the 
cells for at least 20 min at 37°C was not degraded since 
in two experiments 83% of radioactivity was recovered 
after liquid chromatography analysis as the single peak 
corresponding to [14C]paf standard. Three more 
molecules possessing paf-related structures were tested 
next. Among them C18:O lyso paf, the inactive precur- 
sor/metabolite of paf showed to be very active. C16:O 
lyso paf and lyso phosphatidylcholine were less potent 
(Fig. 2) as well as the carbamyl analogue of paf (data 
not shown). The 2-acyl (long chain) analogue of paf, 
hexadecyl-palmitoyl-GPC (10 and 100 ,uM) was ineffec- 
tive. This result led us to reconsider the specificity of 
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Fig. 1. Time-course and dose effects of paf Cl8:O and C16:0-induced 
chemiluminescence on EBV-BLCL. The results are representative of
4 independent experiments. 
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Fig. 2. Time-course of lyso paf ClS:O, Cl6:O and lyso PC-induced 
chemiluminescence on EBV-BLCL. The results are representative of
3 independent experiments. 
paf action on EBV-BLCL. We thus tested three specific 
paf antagonists in order to counteract he paf-induced 
02 formation by cells (Table I). Two of them, BN 
52021 and WEB 2086, possessing structures non-related 
to paf, were inactive. In contrast the paf structural 
analogue CV 3988 inhibited the superoxide formation. 
The latter possessed also an early but weak agonist ef- 
fect. In the above experiments all phospholipids tested 
were slightly toxic to cells since the cell viability (deter- 
mined by the Trypan blue dye exclusion test) decreased 
from 95% to 80% after a 10 min incubation with 
phospholipids. 
Taken together our data fit with detergent-like action 
of paf on EBV-BLCL rather than with a receptor- 
mediated process. First, the potency of paf with respect 
Table I 
Effect of paf inhibitors (BN, WEB and CV) on paf and lyso paf 
stimulated CL in EBV-B cells 
Inhibitors None paf Cl8:O paf Cl6:O Lyso-paf Cl8:O 
None 236 + 40 6200 + 656 2360 f 525 3450 f 150 
BN 52021 
lo-3M 246 + 25 5483 f 382 2116 + 275 3100 * 264 
lo-4M 183 + 35 5667 + 252 NT NT 
WEB 2086 
lo-4M 300 + 50 5250 + 229 1916 + 202 3083 f 252 
lo-5M 180+ 30 603Ozt305 NT NT 
CV 3988 
lo-3M 1570 t 202” 933 + 104 746 + 126 990 f 185 
lo-4M 873 + 136a 4133 f 351 NT NT 
a Effect of CV alone after 1 min incubation with B cells (the CL 
decreased to 700 cpm and 350 cpm after 3 min for lo-’ M and 
10e4 M, respectively) 
lo6 EBV-BLBL were stimulated with lo-’ M paf Cl8:0, Cl6:O and 
lyso paf Cl8:O in the presence and absence of 1 min preincubation of 
the different inhibitors. CL (in cpm) was measured at 3 min 
corresponding to the peak of the response. The controls contained 
buffer with or without inhibitors. Results represented mean f SD 
(n = 3) 
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to 0; formation is very similar to that of lyso paf con- 
firming former findings that the substitution of a 
hydroxyl group by a methyl, acetyl or benzyl group are 
without major effects on the hemolytic activity of such 
molecules [14]. In the majority of cellular or tissue 
models lyso paf is inactive in the non-lytic concentra- 
tion range [2]. However, paf and lyso paf at 
micromolar concentrations, close to the critical 
micellar concentration are membrane perturbants [151. 
Second, the superoxide anion formation by paf- 
challenged EBV-BLCL was not inhibited by both 
specific paf antagonists BN 52021 and WEB 2086. The 
inhibition of 02 release by CV 3988 might be attributed 
to the incorporation of this molecule into the cell mem- 
brane leading to a protection of the latter against paf 
attack. Third, several authors reported that the 
biological activity of C16:O paf was 2-3 times superior 
to that of C18:O paf (reviewed in [16]). In our hands the 
same paf dilutions tested for platelet aggregating activi- 
ty revealed that C16:O paf was 2- to 3-fold more potent 
than its C18:O analogue. In contrast, when using the 
superoxide formation test on EBV-BLCL, C18:O paf 
was about 3-fold more active than its C16:O analogue. 
Is the phospholipid-initiated superoxide production 
by B cells physiologically meaningful? In the inflam- 
matory site paf and lyso paf concentration might be 
high since the stimulated polymorphonuclear 
neutrophils and monocyte/macrophages are a huge 
source of paf [2]. 
The small alterations induced in the cell membrane 
phospholipid (short chain) content may give rise to sub- 
tle changes of cellular surface appearance. This, 
together with the effects of these detergents on 
membrane-bound enzymes [15], would indicate a role 
of these molecules in membrane properties involved in 
the surface recognition process. Clinical trials using paf 
analogues that resist normal phospholipid metabolism, 
based on the idea of controlling cellular surface proper- 
ties by pharmacological means are presently performed 
[17]. The present work shows that such phar- 
macological manipulations may elicit unexpected func- 
tional patterns among target cells. 
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